Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Liraglutide and Insulin-001 A Randomized Prospective Trial of Liraglutide Added to High-Dose Insulin Therapy vs. High-Dose Insulin Therapy Alone in Insulin-Resistant Patients With Type 2 Diabetes

NCT01654120 is registered in ClinicalTrials.gov with Mountain Diabetes and Endocrine Center as lead sponsor.

NCT NCT01654120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01654120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Liraglutide and Insulin-001 A Randomized Prospective Trial of Liraglutide Added to High-Dose Insulin Therapy vs. High-Dose Insulin Therapy Alone in Insulin-Resistant Patients With Type 2 Diabetes
Lead sponsor
Mountain Diabetes and Endocrine Center
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2011
Completion date
November 30, 2013
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type ii